Brexit and beyond: the challenges ahead for pharmaBrexit, and the political fallout from approving any deal, will continue to dominate British politics in 2019. It Share XBrexit and beyond: the challenges ahead for pharmahttps://pharmaphorum.com/views-analysis-sales-marketing/brexit-challenges-ahead-pharma/
Women in Science: AstraZenecaWe speak to three of AstraZeneca’s senior leaders about their careers, the future of their therapy areas and Share XWomen in Science: AstraZenecahttps://pharmaphorum.com/r-d/views-analysis-r-d/women-in-science-astrazeneca/
Young advocate’s patient voice heard at top levels of powerListening to the patient voice gives industry the opportunity to learn about the challenges people with long-term conditions Share XYoung advocate’s patient voice heard at top levels of powerhttps://pharmaphorum.com/views-analysis-patients/young-advocates-patient-voice/
Adding value to generics and biosimilarsPaul Tredwell, vice president for specialty brands at Accord Healthcare says innovation is vital for success in today’s Share XAdding value to generics and biosimilarshttps://pharmaphorum.com/r-d/views-analysis-r-d/adding-value-to-generics-and-biosimilars/
The age of digital medicine is hereAs technology and traditional healthcare converge, some trends in cutting-edge digital health innovation are emerging. Andrew Thompson, CEO Share XThe age of digital medicine is herehttps://deep-dive.pharmaphorum.com/magazine/disruptive-technologies/the-age-of-digital-medicine-is-here/
R&D roundup – Sage impresses at JP MorganOne of the biggest headline-grabbers at the 2019 JP Morgan Healthcare conference this week was Sage Therapeutics unveiling Share XR&D roundup – Sage impresses at JP Morganhttps://pharmaphorum.com/r-d/views-analysis-r-d/rd-roundup-sage-impresses-at-jp-morgan/
Mandatory or voluntary? A sticking point for European HTAThe long road to unified European Health Technology Assessment (HTA) is continuing. It has become clear that the Share XMandatory or voluntary? A sticking point for European HTAhttps://pharmaphorum.com/views-analysis-market-access/mandatory-or-voluntary-a-sticking-point-for-european-hta/
Listening to the patient voice: severe sickness in pregnancyWith new knowledge comes new possibilities, but only if the patient voice isn’t drowned out by stigma and Share XListening to the patient voice: severe sickness in pregnancyhttps://pharmaphorum.com/views-analysis-patients/listening-to-the-patient-voice-severe-sickness-in-pregnancy/
The constants of pharma marketingVeteran marketer Neal Wolff’s career has taken him from big pharma to US-based biotech Nevakar. We spoke to Share XThe constants of pharma marketinghttps://pharmaphorum.com/views-analysis-sales-marketing/the-constants-of-pharma-marketing/
